• Addex to lead mGlu7 NAM-focused PTSD consortium pharmaceutical-technology
    July 10, 2019
    Swiss-headquartered Addex Therapeutics has announced it will lead a consortium to develop small molecule negative allosteric modulators (NAMs) indicated to reduce fear memory in post-traumatic stress disorder (PTSD).
PharmaSources Customer Service